Key result
Statins anchor pediatric familial hypercholesterolemia management, but achieving target LDL-C often requires early combination therapy.
Why the study?
Familial hypercholesterolemia elevates LDL-C from birth and accelerates early atherosclerosis, offering an opportunity for prevention in childhood through contemporary pharmacotherapy.
What are the efficacy, safety, and dosing recommendations of contemporary lipid-lowering pharmacotherapies in children and adolescents with familial hypercholesterolemia?
What are the efficacy, safety, and dosing recommendations of contemporary lipid-lowering pharmacotherapies in children and adolescents with familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
This review highlights that while statins remain first-line for pediatric familial hypercholesterolemia, early combination therapy with newer agents is often required to achieve LDL-C targets and prevent early atherosclerosis.
INTRODUCTION: Familial hypercholesterolemia (FH) elevates low-density lipoprotein cholesterol (LDL-C) from birth, accelerating early atherosclerosis and offering an opportunity for prevention in childhood. AREAS COVERED: This review addresses diagnosis and treatment of heterozygous and homozygous FH in children and adolescents, covering statins, ezetimibe, PCSK9 monoclonal antibodies, inclisiran, bile acid sequestrants, bempedoic acid, evinacumab, lomitapide, and lipoprotein apheresis. Pediatric dosing, efficacy, safety, vascular effects, follow-up, and recommendations are evaluated. Sources include PubMed/MEDLINE publications through September 2026, guidelines, consensus statements, and FDA/EMA information. EXPERT OPINION: Statins remain first-line therapy, but LDL-C targets often require early combination treatment to minimize lifelong exposure. Evidence is strongest for short-term lipid lowering and statin safety; outcome trials are impractical, and long-term data for newer drugs remain limited. Registries should assess sustained safety, adherence, development, imaging, and cardiovascular outcomes. Underdiagnosis and unequal access remain major barriers. Screening with cascade testing, genotype-informed treatment, long-acting PCSK9-directed therapies, and LDL receptor-independent approaches for homozygous FH will likely shape care. Earlier diagnosis and prompt treatment intensification should prioritize preventing atherosclerosis onset.
No takes yet. Share an insight, caveat, or question.
Juliani et al. (2026) conducted a review in Heterozygous and homozygous familial hypercholesterolemia. Statins, ezetimibe, PCSK9 monoclonal antibodies, inclisiran, bile acid sequestrants, bempedoic acid, evinacumab, lomitapide, and lipoprotein apheresis was evaluated on LDL-C lowering, safety, and vascular effects. Statins remain first-line therapy for pediatric familial hypercholesterolemia, though achieving LDL-C targets often requires early combination treatment to minimize lifelong exposure.
Synapse has enriched 10 related papers. Consider them for comparative context: